Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jan 29.

Published in final edited form as: Leuk Lymphoma. 2010 Feb;51(2):243–251. doi: 10.3109/10428190903480728

A. Differences in pre-mobilization marrow plasmacytosis as a function of novel induction regimen utilized. Patients were stratified by the type of novel induction agent received, either thalidomide-, lenalidomide-, bortezomib-, or combination (i.e., VTD or VRD)- based. A significant difference was observed between groups. Planned comparisons revealed that the combination induction regimens led to significantly less residual marrow plasmacytosis than lenalidomide-based induction (*).

Figure 1B. Differences in day 1 peripheral blood CD34(+) cell count as a function of novel induction regimen utilized. Patients were stratified as in Fig 1A. A significant difference was observed between groups and planned comparisons revealed that patients receiving bortezomib-based induction had higher peripheral blood CD34(+) cell counts than others (*).

Figure 1C. Differences in day 1 CD34(+) cell collection as a function of novel induction regimen utilized. Patients were stratified as in Fig 1A. A significant difference in day 1 CD34(+) cell collection was observed between groups and planned comparisons revealed that patients receiving bortezomib-based induction had higher day 1 CD34(+) cell collections than others (*).

A. Differences in pre-mobilization marrow plasmacytosis as a function of novel induction regimen utilized. Patients were stratified by the type of novel induction agent received, either thalidomide-, lenalidomide-, bortezomib-, or combination (i.e., VTD or VRD)- based. A significant difference was observed between groups. Planned comparisons revealed that the combination induction regimens led to significantly less residual marrow plasmacytosis than lenalidomide-based induction (*).

Figure 1B. Differences in day 1 peripheral blood CD34(+) cell count as a function of novel induction regimen utilized. Patients were stratified as in Fig 1A. A significant difference was observed between groups and planned comparisons revealed that patients receiving bortezomib-based induction had higher peripheral blood CD34(+) cell counts than others (*).

Figure 1C. Differences in day 1 CD34(+) cell collection as a function of novel induction regimen utilized. Patients were stratified as in Fig 1A. A significant difference in day 1 CD34(+) cell collection was observed between groups and planned comparisons revealed that patients receiving bortezomib-based induction had higher day 1 CD34(+) cell collections than others (*).